Featured News

The Celiac Disease Foundation is proud to have been involved by recruiting patients essential for this trial’s success.

The Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) study is revealing how genetic and lifestyle factors make children susceptible to autoimmune diseases such as celiac disease, inflammatory bowel disease, and multiple sclerosis.

Initial findings of the first mass screening study for U.S. children show a high prevalence of celiac disease autoimmunity (CDA) among those without symptoms and no family history of the condition.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

A new intensive study confirms that people with celiac disease are frequently exposed to gluten in food.

A new Alcohol and Tobacco Tax and Trade Bureau (TTB) ruling released October 13 allows a gluten-free label on spirits distilled from gluten-containing grains.

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.

The following study, which examines the prevalence of dermatitis herpetiformis (DH), was made possible by the Foundation’s iCureCeliac® patient registry.

New research from Columbia University revealed differences in the antibodies present, adding evidence that NCGS involves a different kind of inflammation in the gut in response to gluten.

The Celiac Disease Foundation through the generosity of Proud Sponsor Schar is providing reimbursement grants to dietitians who complete all five COT modules.